Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UNC-51-like autophagy-activating kinase 1 (ULK1) is a critical serine/threonine kinase that serves as the primary initiator of the macroautophagy pathway in mammalian cells (UniProt, P42768). It functions as the catalytic subunit of the ULK complex, which integrates signals from metabolic sensors like mTORC1 and AMPK to trigger autophagosome formation (PubMed, 29233870). In the context of oncology, ULK1 is often upregulated to promote tumor cell survival under nutrient-deprived conditions and to facilitate resistance against chemotherapy and targeted therapies (PubMed, 30554882). Conversely, its dysregulation is linked to the pathogenesis of neurodegenerative diseases, where inadequate autophagy leads to the toxic accumulation of misfolded proteins (PubMed, 31160674). Pharmacological modulation of ULK1 is an active area of research, with inhibitors like DCC-3116 currently in clinical trials to enhance the efficacy of MAPK pathway inhibitors in RAS-mutated cancers (, NCT04892501). Additionally, small-molecule activators are being explored for their potential to restore autophagic flux in proteinopathies and metabolic disorders (PubMed, 28846096).
Small-molecule inhibition of the ULK1 kinase domain to block autophagosome initiation and sensitize cells to metabolic stress (PubMed, 25915708).
4 more in the full profile.
Source types: Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine/threonine-protein kinase ULK1 (ULK1) (ULK1).